Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 35 min ago
Peer-reviewedCC BY-NC 4.0Pulmonary Circulation

Cardiac Output and Oxygen Delivery Responses to Sotatercept in Pulmonary Arterial Hypertension

  1. 1Department of Pulmonary and Critical Care Medicine Integrated Hospital‐Care Institute, Cleveland Clinic Cleveland Ohio USA
  2. 2Department of Inflammation and Immunity Cleveland Clinic Research, Cleveland Clinic Cleveland Ohio USA
  3. 3Department of Quantitative Health Sciences Lerner Research Institute, Cleveland Clinic Cleveland Ohio USA

Abstract

Sotatercept, a first‐in‐class activin signaling inhibitor, improves pulmonary vascular hemodynamics and clinical outcomes in pulmonary arterial hypertension (PAH). However, despite reductions in mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR), cardiac output (CO) does not generally increase, and some patients experience a decline in CO, a finding of unclear clinical significance. We sought to characterize the heterogeneity of CO responses to sotatercept in PAH and to determine whether incorporating oxygen delivery (DO2) provides additional insight into the physiological significance of these changes. We retrospectively analyzed PAH patients who underwent right heart catheterization before and during sotatercept therapy (median 7.3 months, IQR 4.8, 9.3). Hemodynamic, echocardiographic, hematologic, and clinical parameters were collected, including functional class, 6‐min walk distance (6MWD) and N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP). Patients were dichotomized by CO response (decreased vs. maintained), and DO2 was calculated at each catheterization. A total of 56 patients were included. While most demonstrated reductions in PVR and mPAP, 63% experienced decreased CO. Improvements in 6MWD and NT‐proBNP were similar between groups, and hemoglobin increased comparably. However, among patients with decreased CO, 63% had a concomitant decline in DO2 accompanied by worsening 6MWD and a reduced NT‐proBNP response. In this real‐world cohort, over half of sotatercept‐treated PAH patients experienced reduced CO despite overall hemodynamic and clinical improvement. Concomitant reductions in DO2 identify a subgroup with worse functional outcomes. These findings suggest that DO2 adds additional information beyond CO alone when assessing the physiological response to sotatercept.

Related

  1. Sotatercept-related peripheral microvascular alterations in systemic sclerosis–associated pulmonary arterial hypertension: insights from nailfold capillaroscopy
    Yuichiro Segawa, Takehiro Takahashi, Jun Yamamoto +12
    Rheumatology Advances in PracticePeer-reviewedCC BY 4.0Full textGeneral medicinePMCEurope PMC
  2. Case Report: Upfront sotatercept-based triple therapy in high-risk systemic sclerosis-associated pulmonary arterial hypertension
    Yuichi Tamura, Sarasa Isobe, Hiroyuki Fujii +2
    Frontiers in Cardiovascular MedicinePeer-reviewedCC BY 4.0Full textCardiovascular medicineCrossrefEurope PMC
  3. Novel cardiovascular magnetic resonance imaging biomarkers to track response to treatment including Sotatercept in a patient with idiopathic pulmonary arterial hypertension: a case report.
    Alessandro Castiglione, Barbro Kjellström, Göran Rådegran +1
    European heart journal. Case reportsPeer-reviewedCC BY-NCFull textCardiovascular medicineEurope PMCPMC
  4. Salvage Use of Sotatercept for Potts Shunt in Refractory Pulmonary Hypertension.
    Zhuoyuan Xu, Mingjie Zhang, Yiwei Chen +6
    Pulmonary circulationPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  5. Sotatercept as a Treatment for Pulmonary Hypertension Associated With Connective Tissue Disease and ILD.
    Fernando Vargas-Ursúa, Alejandro Cruz-Utrilla, Andrés Tenes
    Open respiratory archivesPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCPMC
BibTeX
@article{stockdale2026cardiac,
  title = {{Cardiac Output and Oxygen Delivery Responses to Sotatercept in Pulmonary Arterial Hypertension}},
  author = {Graham Stockdale and Adriano R. Tonelli and Alice Goyanes and Matthew T. Siuba and Pradhab Kirupaharan and Neal F. Chaisson and Kristin Highland and Joseph Parambil and Yifan Wang and Gustavo Heresi and Samar Farha},
  journal = {Pulmonary Circulation},
  year = {2026},
  month = nov,
  doi = {10.1002/pul2.70454},
  url = {https://doi.org/10.1002/pul2.70454},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Cardiac Output and Oxygen Delivery Responses to Sotatercept in Pulmonary Arterial Hypertension
AU  - Graham Stockdale
AU  - Adriano R. Tonelli
AU  - Alice Goyanes
AU  - Matthew T. Siuba
AU  - Pradhab Kirupaharan
AU  - Neal F. Chaisson
AU  - Kristin Highland
AU  - Joseph Parambil
AU  - Yifan Wang
AU  - Gustavo Heresi
AU  - Samar Farha
PY  - 2026
DA  - 2026/11/12
JO  - Pulmonary Circulation
DO  - 10.1002/pul2.70454
UR  - https://doi.org/10.1002/pul2.70454
AB  - Sotatercept, a first‐in‐class activin signaling inhibitor, improves pulmonary vascular hemodynamics and clinical outcomes in pulmonary arterial hypertension (PAH). However, despite reductions in mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR), cardiac output (CO) does not generally increase, and some patients experience a decline in CO, a finding of unclear clinical significance. We sought to characterize the heterogeneity of CO responses to sotatercept in PAH and to determine whether incorporating oxygen delivery (DO2) provides additional insight into the physiological significance of these changes. We retrospectively analyzed PAH patients who underwent right heart catheterization before and during sotatercept therapy (median 7.3 months, IQR 4.8, 9.3). Hemodynamic, echocardiographic, hematologic, and clinical parameters were collected, including functional class, 6‐min walk distance (6MWD) and N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP). Patients were dichotomized by CO response (decreased vs. maintained), and DO2 was calculated at each catheterization. A total of 56 patients were included. While most demonstrated reductions in PVR and mPAP, 63% experienced decreased CO. Improvements in 6MWD and NT‐proBNP were similar between groups, and hemoglobin increased comparably. However, among patients with decreased CO, 63% had a concomitant decline in DO2 accompanied by worsening 6MWD and a reduced NT‐proBNP response. In this real‐world cohort, over half of sotatercept‐treated PAH patients experienced reduced CO despite overall hemodynamic and clinical improvement. Concomitant reductions in DO2 identify a subgroup with worse functional outcomes. These findings suggest that DO2 adds additional information beyond CO alone when assessing the physiological response to sotatercept.
SN  - 2045-8932
SN  - 2045-8940
ER  -